CF Foundation Invests in SalioGen’s Gene Coding Therapy

CF Foundation Invests in SalioGen’s Gene Coding Therapy

315664

CF Foundation Invests in SalioGen’s Gene Coding Therapy

The Cystic Fibrosis Foundation has announced an investment in SalioGen Therapeutics to support the company’s preclinical research toward  developing a new gene therapy for cystic fibrosis (CF). SalioGen is working to advance a novel type of gene therapy, called Gene Coding, which is accomplished using the company’s Exact DNA Integration Technology, or EDIT. This technology aims to insert new pieces of DNA into specific places in a cell’s genetic code, which could be exploited to…

You must be logged in to read/download the full post.